The GPIIbIIIa antagonist drugs eptifibatide and tirofiban do not induce activation of apoptosis executioner caspase-3 in resting platelets but inhibit caspase-3 activation in platelets stimulated with thrombin or calcium ionophore A23187

Reagents and solutions
Integrilin (eptifibatide, 0.75 mg/mL) was purchased from Millennium Pharmaceuticals Inc. (Cambridge, MA) and Aggrastat (tirofiban hydrochloride, 50 µg/mL) was from Medicure Pharma Inc. (Somerset, NJ). Gly-Pro-Arg-Pro (GPRP) peptide was purchased from Sigma (St. Louis, MO), human α-thrombin was from Haematologic Technologies Inc (Crossing, VT), A23187 was from Calbiochem (San Diego, CA) and FAM-DEVD-FMK (carboxyfluorescein-carbonyl-aspartyl-glutamyl-valyl-aspartic acid fluoromethyl ketone) was from Chemicon International (Temecula, CA). Control diluent buffer A was composed of phosphate buffered saline (Invitrogen, Carlsbad, CA) supplemented with 1 mM MgCl2, 5.6 mM glucose, 0.1% BSA and 10 mM HEPES, pH 7.4.

Treatment of platelets with GPIIbIIIa antagonists, thrombin and A23187, and determination of caspase-3 activation
In order to mimic an in vivo situation, in this study, we used platelet-rich plasma (PRP), rather than washed platelets, to investigate the effect of Integrilin and Aggrastat on caspase-3 activation in the presence of plasma proteins.

Venous blood from healthy volunteers was anticoagulated with 0.32% sodium citrate and PRP was obtained by centrifugation at 180 g for 15 min at room temperature (RT). Caspase-3 activation was determined as previously described using the cell-penetrating carboxyfluorescein-labeled FAM-DEVD-FMK probe, which covalently binds to active caspase-3. To study the effect of Integrilin and Aggrastat on caspase-3 activation in resting platelets, GPIIbIIIa antagonists at final concentrations of 0.48-4.8 µM or control diluent buffer A were incubated with citrated PRP for 45 min at RT. In platelets stimulated with thrombin or A23187, GPIIbIIIa antagonists at final concentration of 0.48 µM or buffer A were preincubated with PRP for 30 min at RT followed by incubation for 15 min at RT with either 1 U/mL human-α thrombin plus 2.5 mM GPRP or 10 µM A23187 (final concentrations).

For detecting caspase-3 activation, 5 µL aliquots of 10X working FAM-DEVD-FMK solution, prepared according to the manufacturer’s recommendations, were added to 45 µL of treated platelet samples and incubated for 60 min at 37°C in the dark. Following dilution to 500 µL with buffer A, samples were acquired within 30-60 min, fluorescent (FL1) histograms were analyzed, and caspase-3 activation was quantified as the mean channel fluorescence (MCF) of platelet-bound FAM-DEVD-FMK.

Calculation of inhibitory effect of GPIIbIIIa antagonists on caspase-3 activation
To quantify the impact of Integrilin and Aggrastat on caspase-3 activation in platelets stimulated with thrombin and A23187, the percentage of inhibition of caspase-3 activation was calculated in each experiment by the formula:

\[ \text{Inhibition, } \% = \left( \frac{\text{AG} - \text{AN}}{\text{AG} - \text{CON}} \right) \times 100\% \]

where AG: caspase-3 activation in platelets treated with agonist (thrombin or A23187), AN: caspase-3 activation in platelets treated with GPIIbIIIa antagonist (Integrilin or Aggrastat) plus platelet agonist, and CON: caspase-3 activation in platelets treated with control diluent buffer A.

Statistical analysis
Data of seven experiments are presented as means ± SEM. The statistical significance of the differences between different platelet groups was determined by one-way ANOVA with Dunnett’s multiple comparison post hoc test. Differences were considered significant when p<0.05.

Valery Leytin,1,2,3 Asuman Mutlu,1 Sergiy Mykhaylov,1 David J. Allen,1 Armen V. Gyulkhandanyan,1 and John Freedman1,2,3
1Division of Transfusion Medicine, Department of Laboratory Medicine, The Keenan Research Centre in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital, Toronto; 2Toronto Platelet Immunobiology Group, Toronto; 3Departments of Laboratory Medicine and Pathobiology, and Medicine, University of Toronto, Toronto, ON, Canada

Citation: Leytin V, Mutlu A, Mykhaylov S, Allen DJ, Gyulkhandanyan AV, and Freedman J. The GPIIbIIIa antagonist drugs eptifibatide and tirofiban do not induce activation of apoptosis executioner caspase-3 in resting platelets but inhibit caspase-3 activation in platelets stimulated with thrombin or calcium ionophore A23187. Haematologica 2009; 94:1783-1784. doi: 10.3324/haematol.2009.012708

References